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AMPK

:   5′ adenosine monophosphate‐activated protein kinase

CREB

:   cAMP response element binding

MOMP

:   mitochondrial outer membrane permeabilization

PLD

:   phosphatidylcholine hydrolyzing phospholipase D

RISK

:   reperfusion injury salvation kinase

ROS

:   reactive oxygen species

SENP3

:   SUMO1/Sentrin/SMT3‐specific peptidase 3

SLP2

:   stomatin‐like‐protein 2

Introduction {#prp2235-sec-0001}
============

Under both physiological and pathological conditions, mitochondria change their shape through fusion and fission. These processes play central roles in quality control of mitochondria and are important for maintaining various cellular functions and viability, as well as regulating bioenergetic metabolism. Mitochondrial fusion is required for appropriate distribution of mitochondrial DNA, lipids, and proteins across all mitochondria. The main purpose of fusion is to ensure optimal conditions for mitochondria to carry out key cellular processes, such as energy metabolism, cellular differentiation, and calcium homeostasis (Palmer et al. [2011](#prp2235-bib-0051){ref-type="ref"}). A homogeneous mix of mitochondrial matrix proteins, mitochondrial DNA, and maintenance of optimal pH and mitochondrial membrane potential are essential for successful mitochondrial fusion (Kane and Youle [2010](#prp2235-bib-0032){ref-type="ref"}). Mitochondrial fusion is thus a complex sequential process which involves integration of the outer mitochondrial membrane, inner mitochondrial membrane, and matrix content. The main regulators of these processes are the GTP‐ase dynamin‐related proteins: mitofusin 1 (Mfn1), mitofusin 2 (Mfn2), and optical atrophy 1 (Opa1). Other profusion proteins include prohibitin 2, stomatin‐like‐protein 2 (SLP2), and the phosphatidylcholine hydrolyzing phospholipase D (PLD) (Fig. [1](#prp2235-fig-0001){ref-type="fig"}). The integration of theses enzymatic processes has been reviewed elsewhere and will not be detailed here (Palmer et al. [2011](#prp2235-bib-0051){ref-type="ref"}; Da Silva et al. [2014](#prp2235-bib-0018){ref-type="ref"}; Kasahara and Scorrano [2014](#prp2235-bib-0034){ref-type="ref"}).

![Mitochondrial fusion and fission cycle and its key players. (A) Mitochondrial interconnectivity is maintained by fusion which is regulated by proteins such as Mfn1, Mfn2, Opa1, SLP2, and PLD. Mitochondrial fragmentation follows fission, governed by several factors including Fis1, MiD49/51, Mff, miR‐30, miR‐499, and Drp1. Mitochondrial fission is suppressed via inhibition of Drp1 by the synthetic small molecule Mdivi‐1. (B) Proposed binding orientation of Mdivi‐1 (green carbons, sticks) to Drp1 (gray, surface rendered). Mdivi‐1 was computationally docked onto the Drp1 crystal structure (Wenger et al. [2013](#prp2235-bib-0076){ref-type="ref"}) using default conditions for the Geom‐dock module in Sybyl‐X 2.1.1 (Certara L.P.). Shown is a representative of the highest scoring cluster of solutions. Drp1, dynamin‐related protein 1; Fis1, fission 1; Mff, mitochondrial fission factor; Mfn1, mitofusin 1; Mfn2, mitofusin 2; MiD49/51, mitochondrial dynamics protein‐49/51; miR30/499, micro‐RNA 30/499; Opa1, optic atrophy protein; PLD, phosphatidylcholine hydrolyzing phospholipase D; SLP2, stomatin like protein‐2.](PRP2-4-e00235-g001){#prp2235-fig-0001}

The opposite process, mitochondrial fission, plays an important role in mitochondrial proliferation following mitosis and is involved in removing damaged mitochondria from the cells through mitophagy (Otera and Mihara [2012](#prp2235-bib-0050){ref-type="ref"}). Mitochondrial fission is regulated by the large GTP‐ase dynamin‐related protein, Drp1 (the human homolog of the yeast mitochondrial dynamin, Dnm1). Similar to other dynamin‐related proteins, Drp1 has a GTP‐ase effector domain which is important for its GTP‐ase activity. However, it lacks membrane binding domains and thus is heavily dependent on proteins at the outer mitochondrial membrane for anchorage to the mitochondrion (Chan [2012](#prp2235-bib-0011){ref-type="ref"}; Dorn [2013](#prp2235-bib-0019){ref-type="ref"}). These profission docking proteins include Fis1 (mitochondrial fission 1), Mff (mitochondrial fission factor), MiD49 (mitochondrial dynamic protein of 49 kDa), MiD51 (mitochondrial dynamic protein of 51 kDa, also known as mitochondrial elongation factor 1, MIEF1), miR‐30, and miR‐499 (Fig. [1](#prp2235-fig-0001){ref-type="fig"}). Again these mechanisms have been thoroughly reviewed recently (Chan [2012](#prp2235-bib-0011){ref-type="ref"}; Da Silva et al. [2014](#prp2235-bib-0018){ref-type="ref"}; Lee and Yoon [2014](#prp2235-bib-0039){ref-type="ref"}).

Drp1 predominantly localizes in the cytosol as a tetramer and translocates to the outer mitochondrial membrane during mitochondrial fission, where it polymerizes into ring‐like structures around the mitochondria to induce fission (Shin et al. [1999](#prp2235-bib-0063){ref-type="ref"}; Cassidy‐Stone et al. [2008](#prp2235-bib-0010){ref-type="ref"}; Bossy et al. [2010](#prp2235-bib-0008){ref-type="ref"}). Translocation of Drp1 from the cytosol to the mitochondria is regulated by multiple posttranslational modifications including phosphorylation, ubiquitination, SUMOylation, and S‐nitrosylation (Karbowski et al. [2007](#prp2235-bib-0033){ref-type="ref"}; Taguchi et al. [2007](#prp2235-bib-0067){ref-type="ref"}; Wasiak et al. [2007](#prp2235-bib-0075){ref-type="ref"}; Cho et al. [2009](#prp2235-bib-0014){ref-type="ref"}). Phosphorylation is the most well‐studied mechanism, with known sites for phosphorylation being the serine residues 616 and 637 (equivalent to serine 585 and 656 in rats) which promote and inhibit translocation of Drp1 into the mitochondria, respectively (Taguchi et al. [2007](#prp2235-bib-0067){ref-type="ref"}; Qi et al. [2011](#prp2235-bib-0054){ref-type="ref"}).

Mitochondrial dynamics have been implicated in determining survival of many cell types including cardiomyocytes and neurons. Mitochondria fragmented as a result of fission are associated with apoptosis and autophagy (Ong et al. [2010](#prp2235-bib-0048){ref-type="ref"}; Chan [2012](#prp2235-bib-0011){ref-type="ref"}). Shifting the balance of mitochondrial morphology toward fission enhances susceptibility to death in various cell types. In contrast, fused mitochondria are energetically more active, preserve cell functions, and can better withstand oxidative stress (Ong et al. [2010](#prp2235-bib-0048){ref-type="ref"}). The discovery of Mdivi‐1, a small molecule that selectively and reversibly inhibits the mitochondrial fission protein Drp1 (Cassidy‐Stone et al. [2008](#prp2235-bib-0010){ref-type="ref"}), has led to a better understanding of the role of mitochondrial dynamics in the survival of various cell types under different pathophysiological conditions.

Mdivi‐1 as an Inhibitor of Drp1 {#prp2235-sec-0002}
===============================

Mdivi‐1 (mitochondrial fission inhibitor‐1) is the first selective inhibitor of the mitochondrial fission protein Drp1 (Cassidy‐Stone et al. [2008](#prp2235-bib-0010){ref-type="ref"}). It contains a quinazolinone core substituted with a thiol moiety and an aryl (2,4‐dichloro‐5‐methoxyphenyl) side chain attached to the N3 position (Figs. [1](#prp2235-fig-0001){ref-type="fig"}, [2](#prp2235-fig-0002){ref-type="fig"}) (Cassidy‐Stone et al. [2008](#prp2235-bib-0010){ref-type="ref"}; Qian et al. [2015](#prp2235-bib-0058){ref-type="ref"}). Structure--activity relationship analysis has shown that Mdivi‐1 is a mixture of two atropisomers which arise due to hindered rotation at its chiral axis around the nitrogen‐phenyl bond. The axial chirality at the aryl side chain greatly influences the selectivity of Mdivi‐1 for Drp1 (Cassidy‐Stone et al. [2008](#prp2235-bib-0010){ref-type="ref"}; Qian et al. [2015](#prp2235-bib-0058){ref-type="ref"}).

![Pharmacodynamic profile of Mdivi‐1. Mdivi‐1 confers cytoprotection by employing a Drp1‐dependent inhibition of Bax/Bak‐mediated apoptosis, activating the RISK pathway, upregulating mitochondrial large conductance Ca^2+^and voltage activated K^+^ (Mito‐BK) channel as well as reducing ROS. Its cytotoxic effect is exerted independent of Drp1 and through activation of Noxa‐mediated apoptosis. Mdivi‐1 also exerts an inhibitory effect on hyperproliferative cells by inducing G2/M cell cycle arrest and impairs mitosis. Bak, Bcl2‐antagonist/killer 1; Bax, Bcl2‐associated X protein; DNA, deoxyribonucleic acid; Drp1, dynamin‐related protein 1; G2/M, second gap/mitosis; Mito‐BK, mitochondrial big potassium channel; RISK, reperfusion injury salvation kinase; ROS, reactive oxygen species.](PRP2-4-e00235-g002){#prp2235-fig-0002}

Mdivi‐1 has been shown to target Drp1 selectively in mammalian cells by binding at an allosteric site and suppressing Drp1 capacity to catalyze GTP hydrolysis as well as self‐assembly into ring‐like structures around the mitochondria. Mdivi‐1 can induce rapid and reversible formation of interconnected mitochondria without affecting other cellular structures such as the cytoskeleton and endoplasmic reticulum, suggesting selectivity for mitochondrial fission. The half maximal inhibitory concentration of Mdivi‐1 ranges from 1 to 50 *μ*mol/L depending on the cell and assay types (Cassidy‐Stone et al. [2008](#prp2235-bib-0010){ref-type="ref"}; Qian et al. [2015](#prp2235-bib-0058){ref-type="ref"}). Since its discovery in 2008 (Cassidy‐Stone et al. [2008](#prp2235-bib-0010){ref-type="ref"}), Mdivi‐1 has been widely employed as an inhibitor of Drp1 in multiple cell types (Table [1](#prp2235-tbl-0001){ref-type="table-wrap"}) and organs in different disease settings (Table [2](#prp2235-tbl-0002){ref-type="table-wrap"}). Interestingly, Mdivi‐1 exerts divergent effects on cell survival depending on the cell type and experimental setting.

###### 

In vitro studies of Mdivi‐1

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cell types                                             Models                                                        Treatment regimens      Findings                                                            References                                                                                                               
  ------------------------------------------------------ ------------------------------------------------------------- ----------------------- ------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------
  Cardiovascular cells                                                                                                                                                                                                                                                                                                                      

  Cardiomyocytes\                                        Simulated ischemia‐reperfusion injury                         10 & 50 *μ*mol/L        Started 45 min before ischemia                                      ↓Cell death\                                                                                                             (Ong et al. [2010](#prp2235-bib-0048){ref-type="ref"})
  (mouse)                                                                                                                                                                                                          ↑Mitochondrial membrane potential                                                                                        

  Cardiomyocytes\                                        Simulated ischemia‐reperfusion injury                         5 *μ*mol/L              Started 30 min before ischemia                                      ↓Cell death\                                                                                                             (Sharp et al. [2014](#prp2235-bib-0061){ref-type="ref"})
  (mouse)                                                                                                                                                                                                          ↓ROS\                                                                                                                    
                                                                                                                                                                                                                   ↓Cytosolic Ca^2+^\                                                                                                       
                                                                                                                                                                                                                   ↑Oxygen consumption rate\                                                                                                
                                                                                                                                                                                                                   No significant increase in ATP                                                                                           

  Cardiomyocytes\                                        Doxorubicin toxicity                                          1 *μ*mol/L              Cotreatment with doxorubicin                                        Delayed mitochondrial depolarization\                                                                                    (Gharanei et al. [2013](#prp2235-bib-0021){ref-type="ref"})
  (rat)                                                                                                                                                                                                            Delayed hypercontracture                                                                                                 

  HL‐1 cells\                                            Simulated ischemia‐reperfusion injury                         10 & 50 *μ*mol/L        Started 40 min before ischemia                                      ↓Cell death\                                                                                                             (Ong et al. [2010](#prp2235-bib-0048){ref-type="ref"})
  (mouse)                                                                                                                                                                                                          ↑Mitochondria elongation\                                                                                                
                                                                                                                                                                                                                   Delayed mitochondrial depolarization                                                                                     

  HL‐1 cells\                                            ---                                                           1--100 *μ*mol/L         ---                                                                 ↑Firing rate & duration of spontaneous action potential ↓amplitude of I~Kr~\                                             (So et al. [2012](#prp2235-bib-0064){ref-type="ref"})
  (mouse)                                                                                                                                                                                                          ↓Opening probability of K~Ach~                                                                                           

  Vascular smooth muscle cells\                          Idiopathic pulmonary artery hypertension                      5, 10 & 25 *μ*mol/L     ---                                                                 ↓Proliferation\                                                                                                          (Marsboom et al. [2012](#prp2235-bib-0045){ref-type="ref"})
  (human, pulmonary artery)                                                                                                                                                                                        G2/M cell cycle arrest                                                                                                   

  Vascular smooth muscle cells\                          O~2~ challenge on hypoxic cells                               20 *μ*mol/L             During O~2~ challenge                                               ↓Proliferation\                                                                                                          (Hong et al. [2013](#prp2235-bib-0026){ref-type="ref"})
  (human & rabbit, ductus arteriosus)                                                                                                                                                                              ↓Oxygen consumption rate\                                                                                                
                                                                                                                                                                                                                   ↓Pyruvate dehydrogenase activity\                                                                                        
                                                                                                                                                                                                                   ↓mitochondrial H~2~O~2~ production\                                                                                      
                                                                                                                                                                                                                   ↓Ca^2+^ release from mitochondria & ER                                                                                   

  Vascular smooth muscle cells\                          Angiotensin II or H~2~O~2~ treatment                          1, 10 & 20 *μ*mol/L     Cotreatment with Angiotensin or H~2~O~2~\                           ↓Proliferation\                                                                                                          (Lim et al. [2015](#prp2235-bib-0042){ref-type="ref"})
  (rat, aorta)                                                                                                                                 Pretreatment for 60 min                                             G2/M cell cycle arrest\                                                                                                  
                                                                                                                                                                                                                   ↓Migration\                                                                                                              
                                                                                                                                                                                                                   ↑Mitochondrial membrane potential\                                                                                       
                                                                                                                                                                                                                   ↓ROS\                                                                                                                    
                                                                                                                                                                                                                   ↓Phosphorylated ERK1/2, MEK1/2                                                                                           

  Vascular endothelial cells\                            ---                                                           30 *μ*mol/L             24 h                                                                ↑Cell senescence\                                                                                                        (Lin et al. [2015](#prp2235-bib-0043){ref-type="ref"})
  (human, umbilical cord vein)                                                                                                                                                                                     ↓Cell migration\                                                                                                         
                                                                                                                                                                                                                   ↓Angiogenic Tube formation\                                                                                              
                                                                                                                                                                                                                   ↑autophagosomes\                                                                                                         
                                                                                                                                                                                                                   ↓Autolysosomes\                                                                                                          
                                                                                                                                                                                                                   ↑ROS                                                                                                                     

  Neurons                                                                                                                                                                                                                                                                                                                                   

  Neurons\                                               Simulated ischemia‐reperfusion injury                         50 *μ*mol/L             Pretreatment for 40 min                                             ↓Cell death\                                                                                                             (Wang et al. [2014](#prp2235-bib-0072){ref-type="ref"})
  (rat, hippocampus)                                                                                                                                                                                               ↓ROS                                                                                                                     

  Neurons\                                               Simulated epilepsy with magnesium‐free culture                10, 25 & 50 *μ*mol/L    Pretreatment for 30 min                                             ↓Apoptosis\                                                                                                              (Xie et al. [2016](#prp2235-bib-0080){ref-type="ref"})
  (rat, hippocampus)                                                                                                                                                                                               ↓ROS\                                                                                                                    
                                                                                                                                                                                                                   ↓Endoplasmic reticulum stress                                                                                            

  Neurons\                                               Propofol‐induced cell death                                   25 *μ*mol/L             Pretreatment for 60 min                                             ↓Apoptosis\                                                                                                              (Twaroski et al. [2015](#prp2235-bib-0071){ref-type="ref"})
  (human, embryonic stem cell‐derived)                                                                                                                                                                             Delayed mitochondrial depolarization                                                                                     

  Neurons\                                               Glutamate toxicity                                            10 *μ*mol/L             Cotreatment with glutamate                                          ↓Apoptosis\                                                                                                              (Liu et al. [2015](#prp2235-bib-0044){ref-type="ref"})
  (rat, spinal cord)                                                                                                                                                                                               ↓ROS\                                                                                                                    
                                                                                                                                                                                                                   ↑Mitochondrial membrane potential\                                                                                       
                                                                                                                                                                                                                   ↑Antioxidant activity\                                                                                                   
                                                                                                                                                                                                                   ↑Expression of large‐conductance Ca^2+^‐activated K^+^ channel                                                           

  Neurons\                                               Glutamate toxicity or simulated ischemia‐reperfusion injury   25 *μ*mol/L             Cotreatment with glutamate or during simulated ischemia             ↓Apoptosis                                                                                                               (Grohm et al. [2012](#prp2235-bib-0024){ref-type="ref"})
  (rat, cortex)                                                                                                                                                                                                                                                                                                                             

  Neurons\                                               Simulated ischemia‐reperfusion injury                         25 *μ*mol/L             During 4 h of ischemia (cotreatment), without reperfusion\          ↓Cell death (cotreatment)\                                                                                               (Zhang et al. [2013a](#prp2235-bib-0082){ref-type="ref"})
  (rat, cortex)                                                                                                                                During 24 h of reperfusion (posttreatment), after 2 h of ischemia   ↑Cell death (posttreatment)                                                                                              

  Astrocytes\                                            Hypoxia                                                       5‐30 *μ*mol/L           1--24 h                                                             ↑Exogenous ATP metabolism\                                                                                               (Cui et al. [2016](#prp2235-bib-0016){ref-type="ref"})
  (mouse)                                                                                                                                                                                                          ↑Extracellular adenosine\                                                                                                
                                                                                                                                                                                                                   ↑CD39\                                                                                                                   
                                                                                                                                                                                                                   ↑cAMP levels & PKA activity\                                                                                             
                                                                                                                                                                                                                   ↑CREB expression                                                                                                         

  HT22 cells\                                            Glutamate toxicity                                            50 & 75 *μ*mol/L        Cotreatment with glutamate or 2--12 h after glutamate challenge     ↓Apoptosis\                                                                                                              (Grohm et al. [2012](#prp2235-bib-0024){ref-type="ref"})
  (mouse, hippocampal neuronal cells)                                                                                                                                                                              ↑Mitochondrial Membrane potential\                                                                                       
                                                                                                                                                                                                                   ↓ROS & lipid peroxidation\                                                                                               
                                                                                                                                                                                                                   Prevent ATP depletion                                                                                                    

  N27 cells\                                             PINK1‐induced mitochondrial fragmentation                     10 & 30 *μ*mol/L        Cotreatment with ponasterone                                        ↑Mitochondrial membrane potential\                                                                                       (Cui et al. [2010](#prp2235-bib-0015){ref-type="ref"})
  (rat, mesencephalic dopaminergic cells)                                                                                                                                                                          ↑ATP levels                                                                                                              

  Skeletal myoblasts                                                                                                                                                                                                                                                                                                                        

  C2C12\                                                 Palmitate treatment                                           50 & 150 *μ*mol/L       Cotreatment with palmitate for 6 h                                  ↑Glucose uptake\                                                                                                         (Jheng et al. [2012](#prp2235-bib-0029){ref-type="ref"})
  (mouse, skeletal muscle)                                                                                                                                                                                         ↑Mitochondrial membrane potential\                                                                                       
                                                                                                                                                                                                                   ↓ROS                                                                                                                     

  C2C12\                                                 Myogenic differentiation                                      1, 10 & 20 *μ*mol/L     24 h                                                                ↑Apoptosis\                                                                                                              (Kim et al. [2013](#prp2235-bib-0036){ref-type="ref"})
  (mouse, skeletal muscle)                                                                                                                                                                                         Impaired myotube formation\                                                                                              
                                                                                                                                                                                                                   ↓Mitochondrial membrane potential\                                                                                       
                                                                                                                                                                                                                   ↓Mitochondrial mass & DNA\                                                                                               
                                                                                                                                                                                                                   ↓Expression of myogenic regulatory factors, MHC I & creatinine kinase activity                                           

  C2C12\                                                 Oxidative stress                                              25 *μ*mol/L             After H2O2 exposure; for 1 h                                        ↓H~2~O~2~‐induced mitochondrial fragmentation                                                                            (Iqbal and Hood [2014](#prp2235-bib-0028){ref-type="ref"})
  (mouse, skeletal muscle)                                                                                                                                                                                                                                                                                                                  

  L6\                                                    Glucocorticoid‐induced muscle atrophy                         1 *μ*mol/L              Cotreatment with dexamethasone for 6 and 24 h                       ↓Dexamethasone‐induced mitochondrial fission & mitophagy\                                                                (Troncoso et al. [2014](#prp2235-bib-0070){ref-type="ref"})
  (rat, skeletal muscle)                                                                                                                                                                                           ↓oxygen consumption\                                                                                                     
                                                                                                                                                                                                                   ↓autophagic flux                                                                                                         

  Cancer cells                                                                                                                                                                                                                                                                                                                              

  A2780 cells\                                           TRAIL‐induced apoptosis                                       10, 20 & 50 *μ*mol/L    Cotreatment with TRAIL for 16 h                                     ↑Apoptosis\                                                                                                              (Wang et al. [2015a](#prp2235-bib-0073){ref-type="ref"})
  (human, ovarian cancer)                                                                                                                                                                                          ↓Bid expression                                                                                                          

  A2780cis cells\                                        Cisplatin‐induced apoptosis                                   20 & 50 *μ*mol/L        Cotreatment with cisplatin for 20--72 h                             ↑apoptosis\                                                                                                              (Qian et al. [2014](#prp2235-bib-0057){ref-type="ref"})
  (human, cisplatin‐resistant ovarian cancer)                                                                                                                                                                      ↑Bax, Bak & Noxa expression                                                                                              

  A2780cis cells\                                        TRAIL‐induced apoptosis                                       10, 20 & 50 *μ*mol/L    Cotreatment with TRAIL for 16 h                                     ↑Apoptosis                                                                                                               (Wang et al. [2015a](#prp2235-bib-0073){ref-type="ref"})
  (human, cisplatin‐resistant ovarian cancer)                                                                                                                                                                                                                                                                                               

  983A cells\                                                                                                          10--50 *μ*mol/L         Cotreatment with cisplatin for 20 h                                 ↑Apoptosis                                                                                                               (Qian et al. [2014](#prp2235-bib-0057){ref-type="ref"})
  (human, melanoma)                                                                                                                                                                                                                                                                                                                         

  Cal33 cells\                                                                                                         10--50 *μ*mol/L         Cotreatment with cisplatin for 20 h                                 ↑Apoptosis                                                                                                               (Qian et al. [2014](#prp2235-bib-0057){ref-type="ref"})
  (human, head, and neck squamous cell carcinoma)                                                                                                                                                                                                                                                                                           

  Epithelial ovarian cancer cells (human)                Cisplatin‐induced apoptosis                                   20 & 50 *μ*mol/L        Cotreatment with cisplatin for 72 h                                 ↑Apoptosis                                                                                                               (Qian et al. [2014](#prp2235-bib-0057){ref-type="ref"})

  HeLa cells\                                            Staurosporin‐induced apoptosis                                50 *μ*mol/L             Cotreatment with staurosporine for 4 h                              ↓Apoptosis                                                                                                               (Cassidy‐Stone et al. [2008](#prp2235-bib-0010){ref-type="ref"})
  (human, cervical cancer)                                                                                                                                                                                                                                                                                                                  

  LN‐428 cells\                                                                                                        10--50 *μ*mol/L         Cotreatment with cisplatin for 20 h                                 ↑Apoptosis                                                                                                               (Qian et al. [2014](#prp2235-bib-0057){ref-type="ref"})
  (human, glioblastoma)                                                                                                                                                                                                                                                                                                                     

  MDA‐MB‐231 cells (human, breast carcinoma)             ---                                                           20 & 50 *μ*mol/L        48 h                                                                G2/M cell cycle arrest & aneuploidy                                                                                      (Qian et al. [2012](#prp2235-bib-0056){ref-type="ref"})

  MDA‐MB‐231 cells (human, breast carcinoma)             Cisplatin or carboplatin‐induced apoptosis                    10--50 *μ*mol/L         Cotreatment with cisplatin or carboplatin for 2--72 h               ↑Apoptosis\                                                                                                              (Qian et al. [2014](#prp2235-bib-0057){ref-type="ref"})
                                                                                                                                                                                                                   ↓cell proliferation                                                                                                      

  MDA‐MB‐231 cells\                                      ---                                                           10--50 *μ*mol/L         16--48 h                                                            M phase cell cycle arrest\                                                                                               (Wang et al. [2015b](#prp2235-bib-0074){ref-type="ref"})
  (human, breast carcinoma)                                                                                                                                                                                        Abnormal karyokinesis\                                                                                                   
                                                                                                                                                                                                                   Impaired cytokinesis\                                                                                                    
                                                                                                                                                                                                                   Hyperploidy                                                                                                              

  SH‐SY5Y cells\                                         Simulated ischemia‐reperfusion injury                         5, 10 & 20 *μ*mol/L     Started 5 min before ischemia                                       ↑Cell viability\                                                                                                         (Zhao et al. [2014](#prp2235-bib-0085){ref-type="ref"})
  (human, neuroblastoma)                                                                                                                                                                                           ↑Mitochondrial membrane potential\                                                                                       
                                                                                                                                                                                                                   ↑Cellular ATP                                                                                                            

  SH‐SY5Y cells\                                         3NP‐induced autophagy                                         10 *μ*mol/L             Cotreatment with 3NP for 5 h                                        No effect on 3NP‐induced autophagy, ROS production, mitochondrial fragmentation, and Bax translocation to mitochondria   (Solesio et al. [2013](#prp2235-bib-0065){ref-type="ref"})
  (human, neuroblastoma)                                                                                                                                                                                                                                                                                                                    

  MCF7 cells\                                            Mitosis                                                       50 *μ*mol/L             16 h                                                                M phase cell cycle arrest\                                                                                               (Wang et al. [2015b](#prp2235-bib-0074){ref-type="ref"})
  (human, breast carcinoma)                                                                                                                                                                                        Impaired assembly of mitotic spindle & cytokinesis                                                                       

  H1299 cells\                                           Cisplatin‐induced apoptosis                                   10--50 *μ*mol/L         Cotreatment with cisplatin or carboplatin for 2--20 h               ↑Apoptosis\                                                                                                              (Qian et al. [2014](#prp2235-bib-0057){ref-type="ref"})
  (human, nonsmall‐cell lung carcinoma)                                                                                                                                                                            ↑Cleavage of caspase−9 & −3\                                                                                             
                                                                                                                                                                                                                   ↑Cytochrome c release\                                                                                                   
                                                                                                                                                                                                                   ↑Noxa expression                                                                                                         

  H1299 cells\                                           Mitosis                                                       50 *μ*mol/L             8--24 h                                                             ↑Apoptosis\                                                                                                              (Wang et al. [2015b](#prp2235-bib-0074){ref-type="ref"})
  (human, nonsmall‐cell lung carcinoma)                                                                                                                                                                            M phase cell cycle arrest\                                                                                               
                                                                                                                                                                                                                   Impaired assembly of mitotic spindle & cytokinesis                                                                       

  Malignant mesothelioma cells (human)                   PRX3‐deficiency model                                                                                                                                     G2/M cell cycle arrest                                                                                                   (Cunniff et al. [2014](#prp2235-bib-0017){ref-type="ref"})

  Brain tumor initiating cells of glioblastoma (human)   ---                                                           10 & 20 *μ*mol/L        2--4 days                                                           ↑Apoptosis\                                                                                                              (Xie et al. [2015](#prp2235-bib-0079){ref-type="ref"})
                                                                                                                                                                                                                   ↑AMPK activation                                                                                                         

  GH3 cells\                                             ---                                                           30 *μ*mol/L             ---                                                                 ↓Amplitude of I~Kr(ERG)~                                                                                                 (So et al. [2012](#prp2235-bib-0064){ref-type="ref"})
  (rat, pituitary tumor)                                                                                                                                                                                                                                                                                                                    

  HL‐60 cells\                                           Doxorubicin toxicity                                          1 *μ*mol/L              Cotreatment with doxorubicin                                        No effect on doxorubicin‐induced toxicity                                                                                (Gharanei et al. [2013](#prp2235-bib-0021){ref-type="ref"})
  (human, leukemia)                                                                                                                                                                                                                                                                                                                         

  U2OS cells\                                            Mitosis                                                       50 *μ*mol/L             8--24 h                                                             ↑Apoptosis\                                                                                                              (Wang et al. [2015b](#prp2235-bib-0074){ref-type="ref"})
  (human, osteosarcoma)                                                                                                                                                                                            M phase arrest\                                                                                                          
                                                                                                                                                                                                                   Impaired assembly of mitotic spindles & cytokinesis                                                                      

  A375 & A2058 cells\                                    Death receptor‐induced apoptosis                              50 *μ*mol/L             Cotreatment with *α*DR4                                             ↑Apoptosis                                                                                                               (Suzuki‐Karasaki et al. [2015](#prp2235-bib-0066){ref-type="ref"})
  (human, melanoma)                                                                                                                                                                                                                                                                                                                         

  SK‐N‐SH cells\                                         High glucose treatment                                        10 *μ*mol/L             ---                                                                 ↑Mitochondrial density\                                                                                                  (Huang et al. [2015](#prp2235-bib-0027){ref-type="ref"})
  (human, neuroblastoma)                                                                                                                                                                                           ↑complex I activity\                                                                                                     
                                                                                                                                                                                                                   Maintained mitochondrial length                                                                                          

  PC12 cells\                                            Ischemia‐reperfusion injury                                   25, 50 & 100 *μ*mol/L   Pretreatment for 30 min                                             ↓Cell death\                                                                                                             (Tian et al. [2014](#prp2235-bib-0069){ref-type="ref"})
  (rat, pheochromocytoma)                                                                                                                                                                                          ↓ros\                                                                                                                    
                                                                                                                                                                                                                   ↑Mitochondrial membrane potential\                                                                                       
                                                                                                                                                                                                                   ↓Mitochondrial Ca^2+^ uptake & ER Ca^2+^ release                                                                         

  Others                                                                                                                                                                                                                                                                                                                                    

  Immortalized fibroblasts\                              Cisplatin‐induced apoptosis                                   50 *μ*mol/L             Cotreatment with cisplatin for 20 h                                 ↑Apoptosis (Drp1 independent)                                                                                            (Qian et al. [2014](#prp2235-bib-0057){ref-type="ref"})
  (mouse, embryo)                                                                                                                                                                                                                                                                                                                           

  Immortalized fibroblasts\                              ---                                                           20 *μ*mol/L             20 h                                                                ↑Apoptosis (Bax/Bak independent)                                                                                         (Qian et al. [2015](#prp2235-bib-0058){ref-type="ref"})
  (mouse, embryo)                                                                                                                                                                                                                                                                                                                           

  Immortalized fibroblasts\                              Fas‐induced apoptosis                                         50 *μ*mol/L             16 h                                                                ↑Apoptosis (Drp1 & Bax/Bak independent)                                                                                  (Wang et al. [2015a](#prp2235-bib-0073){ref-type="ref"})
  (mouse, embryo)                                                                                                                                                                                                                                                                                                                           

  Immortalized fibroblasts\                              ---                                                           50 *μ*mol/L             6--48 h                                                             ↑Apoptosis (Bax/Bak‐dependent)\                                                                                          (Wang et al. [2015b](#prp2235-bib-0074){ref-type="ref"})
  (mouse, embryo)                                                                                                                                                                                                  M phase cell cycle arrest (Drp1 independent)                                                                             

  Immortalized fibroblasts\                              ---                                                           50 *μ*mol/L             6--24 h                                                             ↑Apoptosis\                                                                                                              (Wang et al. [2015b](#prp2235-bib-0074){ref-type="ref"})
  (human, foreskin)                                                                                                                                                                                                M phase cell cycle arrest                                                                                                

  COS cells\                                             Stausporine‐induced apoptosis                                 1--200 *μ*mol/L         Cotreatment with staurosporine for 4 h                              ↓Apoptosis                                                                                                               (Cassidy‐Stone et al. [2008](#prp2235-bib-0010){ref-type="ref"})
  (monkey, kidney cell line)                                                                                                                                                                                                                                                                                                                

  Immortalized small airway epithelial cells\            Irradiation                                                   50 *μ*mol/L             Started 2 h before irradiation                                      No effect on irradiation‐induced mitochondrial respiratory dysfunction                                                   (Zhang et al. [2013a](#prp2235-bib-0082){ref-type="ref"})
  (human)                                                                                                                                                                                                                                                                                                                                   

  HEK293 cells\                                          Simulated ischemia‐reperfusion injury                         50 *μ*mol/L             4 h                                                                 ↓SENP3‐induced cytochrome c release                                                                                      (Guo et al. [2013](#prp2235-bib-0025){ref-type="ref"})
  (human embryo, kidney cell line)                                                                                                                                                                                                                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

3NP, 3‐nitropropionic acid; AMPK, AMP‐activated protein kinase; ATP, adenosine triphosphate; Bak, bcl2‐antagonist/killer‐1; Bax, bcl2‐associated X protein; Bid, BH3‐interacting domain death agonist; cAMP, cyclic adenosine monophosphate; Chk1, checkpoint kinase 1; CREB, cAMP response element binding; Drp1, dynamin‐related protein 1; ER, endoplasmic reticulum; I~K(erg)~, erg‐mediated K^+^ current; I~Kr~, rapidly activating delayed‐rectifier K^+^ current; I~Na~, Na^+^ current; I~tail~, amplitude of tail current; K~Ach~, muscarinic K^+^ channel; MHC I, myosin heavy chain I; MPTP, mitochondrial membrane permeability transition pore; Noxa, latin for damage, alternative name for immediate‐early‐response protein APR; PKA, protein kinase A; PRX3, Peroxiredoxin 3; ROS, reactive oxygen species; SENP3, SUMO1/Sentrin/SMT3 Specific Peptidase 3; SOD, superoxide dismutase; TRAIL, tumor necrosis factor‐related apoptosis‐inducing ligand.
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###### 

In vivo and ex vivo studies of Mdivi‐1

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Organ/Tissue              Model                                                            Regimen                   Findings                                                                                                                                          Reference                                                                   
  ------------------------- ---------------------------------------------------------------- ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------- --------------------------------------------------------------
  Heart\                    Ischemia‐reperfusion injury                                      0.24 & 1.2 mg/kg          Intravenous; 15 min before ischemia                                                                                                               ↓Infarct size                                                               (Ong et al. [2010](#prp2235-bib-0048){ref-type="ref"})
  (mouse)                                                                                                                                                                                                                                                                                                                                            

  Heart\                    Pressure overload‐induced heart failure                          50 mg/kg                  Intraperitoneal; daily for 7 days                                                                                                                 ↓Apoptosis\                                                                 (Givvimani et al. [2012](#prp2235-bib-0022){ref-type="ref"})
  (mouse)                                                                                                                                                                                                                                                                ↓LV Dysfunction\                                                            
                                                                                                                                                                                                                                                                         ↓Fibrosis\                                                                  
                                                                                                                                                                                                                                                                         ↑Angiogenesis\                                                              
                                                                                                                                                                                                                                                                         ↑Mitochondrial density\                                                     
                                                                                                                                                                                                                                                                         ↓Mitophagy\                                                                 
                                                                                                                                                                                                                                                                         ↓Expression of antiangiogenic factors, MMP‐9 & TIMP‐3                       

  Heart\                    Ischemia‐reperfusion injury and doxorubicin toxicity (ex vivo)   1 *μ*mol/L                Perfusion; Cotreatment with doxorubicin during 120 min reperfusion                                                                                ↓Infarct size\                                                              (Gharanei et al. [2013](#prp2235-bib-0021){ref-type="ref"})
  (mouse)                                                                                                                                                                                                                                                                ↑Coronary flow\                                                             
                                                                                                                                                                                                                                                                         ↓Heart rate\                                                                
                                                                                                                                                                                                                                                                         ↑phosphorylated Akt expression\                                             
                                                                                                                                                                                                                                                                         ↓Phosphorylated Erk1/2 & p53 expression                                     

  Heart\                    Ischemia‐reperfusion injury (ex vivo)                            5 & 25 *μ*mol/L           Perfusion; 10 min before ischemia or during 20 min reperfusion                                                                                    ↑Diastolic function                                                         (Sharp et al. [2014](#prp2235-bib-0061){ref-type="ref"})
  (rat)                                                                                                                                                                                                                                                                                                                                              

  Heart\                    Potassium‐induced cardiac arrest                                 0.24 mg/kg                Intravenous; cotreatment with epinephrine; after cardiopulmonary resuscitation                                                                    ↑Animal survival\                                                           (Sharp et al. [2015](#prp2235-bib-0062){ref-type="ref"})
  (mouse)                                                                                                                                                                                                                                                                ↑Heart rate, stroke volume & neurological outcomes\                         
                                                                                                                                                                                                                                                                         ↓Myocardial lactate production                                              

  Pulmonary artery\         Pulmonary artery hypertension (PAH)                              50 mg/kg                  Intraperitoneal;\                                                                                                                                 ↑Exercise capacity\                                                         (Marsboom et al. [2012](#prp2235-bib-0045){ref-type="ref"})
  (rat)                                                                                                                weekly for 4 weeks (CoCl~2~ study), biweekly for 4 weeks (chronic hypoxia study), or 5 daily injections 3 weeks after monocrotaline‐induced PAH   ↑RV function\                                                               
                                                                                                                                                                                                                                                                         ↓RV hypertrophy\                                                            
                                                                                                                                                                                                                                                                         ↑Hematocrit\                                                                
                                                                                                                                                                                                                                                                         ↓Small pulmonary artery thickness                                           

  Ductus arteriosus\        O~2~‐induced constriction (ex vivo)                              20 *μ*mol/L               30 min before exposure O~2~ (PO~2~ 120 mmHg);\                                                                                                    Prevents O~2~‐induced constriction\                                         (Hong et al. [2013](#prp2235-bib-0026){ref-type="ref"})
  (human & rabbit)                                                                                                     6--14 days in normoxic culture (PO~2~ 140 mmHg);                                                                                                  Prevent closure of ductus arteriosus ↓Smooth muscle cell proliferation\     
                                                                                                                                                                                                                                                                         ↓Fibrosis                                                                   

  Aortic ring\              Carotid artery balloon injury                                    50 mg/kg/day              7 days                                                                                                                                            ↓Neointimal formation\                                                      (Lim et al. [2015](#prp2235-bib-0042){ref-type="ref"})
  (rat)                                                                                                                                                                                                                                                                  ↓Smooth muscle cell proliferation                                           

  Brain\                    Ischemia‐reperfusion injury                                      3 mg/kg                   Intraperitoneal; prior to ischemia                                                                                                                ↓Infarct volume                                                             (Grohm et al. [2012](#prp2235-bib-0024){ref-type="ref"})
  (mouse)                                                                                                                                                                                                                                                                                                                                            

  Brain\                    Ischemia‐reperfusion injury                                      10 & 20 mg/kg             Intraperitoneal                                                                                                                                   ↑Neurological outcome\                                                      (Zhao et al. [2014](#prp2235-bib-0085){ref-type="ref"})
  (mouse)                                                                                                                                                                                                                                                                ↓Infarct volume\                                                            
                                                                                                                                                                                                                                                                         ↓Brain edema\                                                               
                                                                                                                                                                                                                                                                         ↓apoptosis                                                                  

  Brain\                    Ischemia‐reperfusion injury                                      10 & 20 mg/kg             Intraperitoneal; 4 h before ischemia and every 12 h for 10 days after reperfusion                                                                 ↑Animal survival\                                                           (Cui et al. [2016](#prp2235-bib-0016){ref-type="ref"})
  (mouse)                                                                                                                                                                                                                                                                ↓Infarct volume\                                                            
                                                                                                                                                                                                                                                                         ↑cerebral blood flow\                                                       
                                                                                                                                                                                                                                                                         ↓Extracellular ATP\                                                         
                                                                                                                                                                                                                                                                         ↑Extracellular adenosine\                                                   
                                                                                                                                                                                                                                                                         ↑CD39 expression\                                                           
                                                                                                                                                                                                                                                                         ↑Phosphorylation of CREB protein                                            

  Brain\                    Implantation of brain tumor initiating cells of glioblastoma     2.5 mg/kg                 Intravenous; 3 days after tumor implantation, administered for 5 days                                                                             ↑Survival\                                                                  (Xie et al. [2015](#prp2235-bib-0079){ref-type="ref"})
  (mouse)                                                                                                                                                                                                                                                                ↑Tumor latency                                                              

  Brain\                    Traumatic brain injury                                           3 mg/kg                   Intraperitoneal; 10 min after injury                                                                                                              ↑Motoric and cognitive recovery\                                            (Wu et al. [2016](#prp2235-bib-0077){ref-type="ref"})
  (mouse)                                                                                                                                                                                                                                                                ↓Infarct volume\                                                            
                                                                                                                                                                                                                                                                         ↓Brain edema\                                                               
                                                                                                                                                                                                                                                                         ↓Apoptosis                                                                  

  Brain\                    Ischemia‐reperfusion injury                                      0.24 & 1.2 mg/kg          Intravenous; 15 min prior to ischemia                                                                                                             ↓Apoptosis of neuron                                                        (Zhang et al. [2013b](#prp2235-bib-0083){ref-type="ref"})
  (rat)                                                                                                                                                                                                                                                                                                                                              

  Brain\                    Ischemia‐reperfusion injury                                      3 mg/kg                   Intraperitoneal;\                                                                                                                                 No change of infarct volume (cotreatment)\                                  (Zhang et al. [2013c](#prp2235-bib-0084){ref-type="ref"})
  (rat)                                                                                                                During 24 h of focal ischemia (cotreatment), without reperfusion\                                                                                 ↑Infarct volume (posttreatment)                                             
                                                                                                                       During 24 h of reperfusion, after 1 h of focal ischemia (posttreatment)                                                                                                                                                       

  Brain\                    Pilocarpine‐induced seizure                                      0.25 & 1.25 mg/kg         Intravenous; 15 min prior to pilocarpine injection                                                                                                ↓Apoptosis                                                                  (Xie et al. [2013](#prp2235-bib-0078){ref-type="ref"})
  (rat)                                                                                                                                                                                                                                                                                                                                              

  Brain\                    Pilocarpine‐induced seizure                                      1.2 mg/kg                 Intraperitoneal; 30 min prior to pilocarpine injection                                                                                            ↓Apoptosis\                                                                 (Qiu et al. [2013](#prp2235-bib-0059){ref-type="ref"})
  (rat)                                                                                                                                                                                                                                                                  ↓ROS\                                                                       
                                                                                                                                                                                                                                                                         ↑SOD activity\                                                              
                                                                                                                                                                                                                                                                         No effect on latency and intensity of seizure                               

  Brain\                    Cardiac arrest                                                   0.24 & 1.2 mg/kg          Intravenous; after 1 min of restoration of spontaneous circulation                                                                                ↑Survival\                                                                  (Li et al. [2015b](#prp2235-bib-0041){ref-type="ref"})
  (rat)                                                                                                                                                                                                                                                                  ↑Neurological outcome\                                                      
                                                                                                                                                                                                                                                                         ↓Apoptosis                                                                  

  Hippocampus\              Type 2 diabetes                                                  10 & 25 mg/kg             Intravenous; daily for 2 weeks                                                                                                                    ↑Hippocampal long‐term potentiation\                                        (Huang et al. [2015](#prp2235-bib-0027){ref-type="ref"})
  (mouse)                                                                                                                                                                                                                                                                ↑ATP levels\                                                                
                                                                                                                                                                                                                                                                         ↑Complex I activity                                                         

  Spinal cord\              Ischemia‐reperfusion injury                                      1 mg/kg                   Intravenous; at the beginning of ischemia                                                                                                         ↑Neurological outcome\                                                      (Liu et al. [2015](#prp2235-bib-0044){ref-type="ref"})
  (rat)                                                                                                                                                                                                                                                                  ↓Spinal cord edema\                                                         
                                                                                                                                                                                                                                                                         ↑Expression of large‐conductance Ca^2+^ & voltage‐activated K^+^ channels   

  Spinal cord\              Acute spinal cord injury\                                        0.24 & 1.2 mg/kg          Intravenous; 15 min prior to injury                                                                                                               ↑Hind limb motor function\                                                  (Li et al. [2015a](#prp2235-bib-0040){ref-type="ref"})
  (rat)                     (Modified Allen\'s method)                                                                                                                                                                                                                   ↓Apoptosis\                                                                 
                                                                                                                                                                                                                                                                         ↑Mitochondrial membrane potential\                                          
                                                                                                                                                                                                                                                                         ↓ROS\                                                                       
                                                                                                                                                                                                                                                                         ↑Reduced glutathione\                                                       
                                                                                                                                                                                                                                                                         ↑ATP levels                                                                 

  Spinal dorsal horn\       Perineural HIV‐1 gp120‐induced neuropathic pain                  0.3, 1 & 3 *μ*g/10 *μ*L   Intrathecal                                                                                                                                       ↑Mechanical allodynia threshold\                                            (Kanda et al. [2016](#prp2235-bib-0031){ref-type="ref"})
  (rat)                                                                                                                                                                                                                                                                  ↓Mitochondrial superoxide                                                   

  Retina\                   Ischemia‐reperfusion injury                                      50 mg/kg                  Intraperitoneal; 60 min prior to & 6 h after ischemia                                                                                             ↓Apoptosis of retinal ganglion cells\                                       (Park et al. [2011](#prp2235-bib-0052){ref-type="ref"})
  (mouse)                                                                                                                                                                                                                                                                ↓Glial fibrillary acidic protein expression                                 

  Kidney\                   Rhabdomyolysis‐induced acute kidney injury                       50 mg/kg                  Intraperitoneal; 1 h or 12 h prior to rhabdomyolysis induction                                                                                    ↓Apoptosis of tubular epithelial cells\                                     (Tang et al. [2013](#prp2235-bib-0068){ref-type="ref"})
  (rat)                                                                                                                                                                                                                                                                  ↓ROS\                                                                       
                                                                                                                                                                                                                                                                         ↑ATP\                                                                       
                                                                                                                                                                                                                                                                         ↑Creatinin kinase                                                           

  Liver\                    Sepsis                                                           50 mg/kg                  Intraperitoneal; 1 h prior to cecal ligation and puncture                                                                                         ↓Apoptosis of hepatocytes\                                                  (Gonzalez et al. [2014](#prp2235-bib-0023){ref-type="ref"})
  (rat)                                                                                                                                                                                                                                                                  ↑Mitochondrial elongation\                                                  
                                                                                                                                                                                                                                                                         ↑Respiratory complex activity                                               

  Skeletal muscle (mouse)   Leptin deficiency                                                44 mg/kg                  Intraperitoneal; 16 h and 1 h prior to insulin/glucose injection                                                                                  ↓Insulin resistance index (systemic)\                                       (Jheng et al. [2012](#prp2235-bib-0029){ref-type="ref"})
                                                                                                                                                                                                                                                                         ↓Phosphorylated Erk1/2 and p38 MAPK                                         
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

8‐oHdG: 8‐Oxo‐2‐deoxyguanosine; ADP, adenosine diphosphate; AIF, apoptosis‐inducing factor; Akt, AKT8 virus oncogene cellular homolog; ATP, adenosine triphosphate; Bax, bcl2‐associated X protein; Bcl2, B‐cell lymphoma 2; CD39, cluster of differentiation 39; CREB, cAMP response element binding; Drp1, dynamin‐related protein 1; Erk 1/2, extracellular signal‐regulated kinase‐1/2; Fis1, fission 1; gp120, glycoprotein 120; LV, left ventricle; MMP 9, matrix metallopeptidase 9; p53, protein 53; PCNA, proliferating cell nuclear antigen; PO~2~, oxygen pressure; ROS, reactive oxygen species; RV, right ventricle; SOD, superoxide dismutase; TIMP 3, tissue inhibitor of metalloproteinases‐3.
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Divergent Effects of Mdivi‐1 on Cell Survival {#prp2235-sec-0003}
=============================================

The cytoprotective effect of Mdivi‐1 was first demonstrated by Cassidy‐Stone et al. ([2008](#prp2235-bib-0010){ref-type="ref"}). They showed that treatment with Mdivi‐1 significantly reduced mitochondrial fragmentation and apoptosis induced by staurosporine, to an extent similar to that observed in cells expressing the dominant negative Drp1K38A mutant (Cassidy‐Stone et al. [2008](#prp2235-bib-0010){ref-type="ref"}). Furthermore, Mdivi‐1 has been shown to attenuate Bax/Bak‐dependent mitochondrial outer membrane permeabilization (MOMP) induced by caspase 8‐cleaved recombinant Bid (Cassidy‐Stone et al. [2008](#prp2235-bib-0010){ref-type="ref"}). These findings suggested that Mdivi‐1 inhibits Drp1‐mediated mitochondrial fragmentation and the intrinsic apoptotic pathway. Other researchers have since confirmed the cytoprotective effect of Mdivi‐1 in various cell types, particularly in cardiovascular cells and neurons. In contrast, Mdivi‐1 has been shown to exert antiproliferative and cytotoxic effects in hyperproliferative cells such as in tumors and immortalized cells (Table [1](#prp2235-tbl-0001){ref-type="table-wrap"}).

Cardiomyocytes {#prp2235-sec-0004}
--------------

Studies of Mdivi‐1 in cardiomyocytes utilized a wide array of injury models to simulate pathological conditions such as ischemia‐reperfusion injury and doxorubicin‐induced cardiotoxicity (Ong et al. [2010](#prp2235-bib-0048){ref-type="ref"}; Gharanei et al. [2013](#prp2235-bib-0021){ref-type="ref"}; Sharp et al. [2014](#prp2235-bib-0061){ref-type="ref"}). Death of cardiomyocytes and HL‐1 cells (a cardiac cell line derived from a mouse atrial tumor) was moderately repressed when pretreated with Mdivi‐1 prior to ischemic insult (Ong et al. [2010](#prp2235-bib-0048){ref-type="ref"}; Sharp et al. [2014](#prp2235-bib-0061){ref-type="ref"}). The cytoprotective effect of Mdivi‐1 was associated with increased phosphorylation of Drp1 at serine 637, thus preventing translocation of Drp1 into the mitochondria and consequently attenuating mitochondrial fragmentation (Ong et al. [2010](#prp2235-bib-0048){ref-type="ref"}; Sharp et al. [2014](#prp2235-bib-0061){ref-type="ref"}). Mdivi‐1 has also been shown to confer cytoprotection by reducing production of reactive oxygen species (ROS), attenuating cytosolic calcium overload, restoring mitochondrial membrane potential, and delaying hypercontracture of cardiomyocytes in ischemia‐reperfusion injury and doxorubicin‐induced cardiotoxicity (Ong et al. [2010](#prp2235-bib-0048){ref-type="ref"}; Gharanei et al. [2013](#prp2235-bib-0021){ref-type="ref"}; Sharp et al. [2014](#prp2235-bib-0061){ref-type="ref"}).

Interestingly, So et al. ([2012](#prp2235-bib-0064){ref-type="ref"}) recently reported that Mdivi‐1 can alter the electrical activity of HL‐1 cells. Treatment with Mdivi‐1 prolonged the duration of the action potential, but increased the firing rate of spontaneous action potentials, inhibited the rapidly activating, delayed‐rectifier K^+^ current (I~Kr~) and reduced the open probability of the muscarinic inward rectifier K^+^ channels (K~Ach~) (So et al. [2012](#prp2235-bib-0064){ref-type="ref"}). The inhibitory effect of Mdivi‐1 on I~Kr~ was shown to be concentration‐dependent with a half maximal concentration of 11.6 *μ*mol/L, similar to that which showed cytoprotection in other studies (Ong et al. [2010](#prp2235-bib-0048){ref-type="ref"}; So et al. [2012](#prp2235-bib-0064){ref-type="ref"}; Gharanei et al. [2013](#prp2235-bib-0021){ref-type="ref"}; Sharp et al. [2014](#prp2235-bib-0061){ref-type="ref"}). This raises a concern that Mdivi‐1 may have arrhythmogenic side effects.

It is important to note that outcomes of studies in HL‐1 cells and neonatal cardiomyocytes require cautious interpretation for these cells are not truly representative of primary adult cardiomyocytes. Differences in cell morphology, electrophysiology, and biogenesis can contribute to their individual resistance or susceptibility toward pathological stimuli and pharmacological agents (Bass et al. [2001](#prp2235-bib-0005){ref-type="ref"}; Milerova et al. [2010](#prp2235-bib-0046){ref-type="ref"}; Kuznetsov et al. [2015](#prp2235-bib-0038){ref-type="ref"}). Mitochondria in adult cardiomyocytes have spatio‐temporal restraint as well as slower rates of fusion--fission cycle when compared with neonatal cardiomyocytes and HL‐1 cells (Beraud et al. [2009](#prp2235-bib-0007){ref-type="ref"}; Chen et al. [2011](#prp2235-bib-0013){ref-type="ref"}; Piquereau et al. [2013](#prp2235-bib-0053){ref-type="ref"}). The relatively short and discrete mitochondria in adult cardiomyocytes are arranged in a regular pattern between myofibrils alongside the sarcomere. They do not form an interconnected network which might otherwise impose biomechanical restriction during cardiomyocyte contraction (Chen et al. [2011](#prp2235-bib-0013){ref-type="ref"}; Dorn and Kitsis [2015](#prp2235-bib-0020){ref-type="ref"}). In contrast, neonatal cardiomyocytes and HL‐1 cells have relatively longer and more dynamic mitochondria which usually form interconnected networks throughout the cell (Amchenkova et al. [1988](#prp2235-bib-0001){ref-type="ref"}; Anmann et al. [2006](#prp2235-bib-0002){ref-type="ref"}). Furthermore, cellular metabolism in adult cardiomyocytes is more dependent on oxidative phosphorylation, whereas neonatal rat cardiomyocytes and HL‐1 cells rely more on glycolysis (Bass et al. [2001](#prp2235-bib-0005){ref-type="ref"}; Anmann et al. [2006](#prp2235-bib-0002){ref-type="ref"}; Monge et al. [2009](#prp2235-bib-0047){ref-type="ref"}). Taken together, the morphological and bioenergetic differences between these cell types could lead to different outcomes in cell survival within similar experimental settings (Bass et al. [2001](#prp2235-bib-0005){ref-type="ref"}; Milerova et al. [2010](#prp2235-bib-0046){ref-type="ref"}; Kuznetsov et al. [2015](#prp2235-bib-0038){ref-type="ref"}).

Vascular cells {#prp2235-sec-0005}
--------------

Mitochondrial fission is essential in smooth muscle cells for their proliferation and migration, processes that are relevant to several pathophysiological conditions such as premature closure of ductus arteriosus and pulmonary hypertension (Marsboom et al. [2012](#prp2235-bib-0045){ref-type="ref"}; Hong et al. [2013](#prp2235-bib-0026){ref-type="ref"}; Lim et al. [2015](#prp2235-bib-0042){ref-type="ref"}). Under oxidative stress and angiotensin II stimulation, ROS‐induced smooth muscle cell proliferation and migration have been attributed to activation of protein kinase Cδ which phosphorylates Drp1, resulting in translocation of Drp1 to the mitochondria and fission (Hong et al. [2013](#prp2235-bib-0026){ref-type="ref"}; Qi et al. [2013](#prp2235-bib-0055){ref-type="ref"}; Lim et al. [2015](#prp2235-bib-0042){ref-type="ref"}). Thus, Mdivi‐1 has been shown to suppress smooth muscle cell proliferation and migration through attenuation of ROS production and Drp1 phosphorylation (Hong et al. [2013](#prp2235-bib-0026){ref-type="ref"}). In arterial smooth muscle cells derived from subjects with pulmonary arterial hypertension, Mdivi‐1 was shown to suppress cell proliferation in a dose‐dependent manner, an effect attributed to G2/M cell cycle arrest and shown to be independent of cyclin B1/CDK1‐mediated phosphorylation of Drp1 at Serine 616 (Marsboom et al. [2012](#prp2235-bib-0045){ref-type="ref"}).

In addition to regulating proliferation and migration of smooth muscle cells, Drp1‐mediated mitochondrial fission plays an important role in metabolism. Oxygen‐induced mitochondrial fission in smooth muscle cells derived from ductus arteriosus has been shown to increase oxidative metabolism, oxygen consumption, and cytosolic calcium levels, which were all effectively prevented by Mdivi‐1 (Hong et al. [2013](#prp2235-bib-0026){ref-type="ref"}).

In endothelial cells, inhibition of Drp1 with Mdivi‐1 has been reported to induce premature senescence and impair the angiogenic function of human umbilical cord vein endothelial cells by increasing mitochondrial ROS production and reducing autophagic flux (Lin et al. [2015](#prp2235-bib-0043){ref-type="ref"}). These studies suggest a key regulatory role of Drp1 in maintaining vascular homeostasis and angiogenesis, and therefore may be a therapeutic target for vascular repair.

Neurons {#prp2235-sec-0006}
-------

Similar to cardiomyocytes, neurons contain metabolically active mitochondria and are susceptible to bioenergetic dysfunction and cell death. Therefore, preservation of normal mitochondrial function through manipulation of mitochondrial morphology is a potential therapeutic approach to neuroprotection. The cytoprotective effect of Mdivi‐1 in neurons has been well illustrated in several experimental injury models such as simulated ischemia‐reperfusion and toxicity of glutamate and propofol (Zhang et al. [2013b](#prp2235-bib-0083){ref-type="ref"}; Wang et al. [2014](#prp2235-bib-0072){ref-type="ref"}; Liu et al. [2015](#prp2235-bib-0044){ref-type="ref"}; Twaroski et al. [2015](#prp2235-bib-0071){ref-type="ref"}). Mechanistic insights include delayed mitochondrial permeability transition pore opening, preserved mitochondrial membrane potential, increased adenosine levels, attenuated oxidative stress, and reduced endoplasmic reticulum stress (Zhang et al. [2013b](#prp2235-bib-0083){ref-type="ref"}; Wang et al. [2014](#prp2235-bib-0072){ref-type="ref"}; Liu et al. [2015](#prp2235-bib-0044){ref-type="ref"}; Twaroski et al. [2015](#prp2235-bib-0071){ref-type="ref"}; Xie et al. [2016](#prp2235-bib-0080){ref-type="ref"}). Cui et al. ([2016](#prp2235-bib-0016){ref-type="ref"}) demonstrated that Mdivi‐1 increases release of the neuroprotective agent, adenosine, through the cAMP/PKA/CREB pathway. Under oxidative stress, ROS trigger apoptotic cell death by increasing intracellular calcium levels and promoting outer mitochondrial membrane permeabilization, leading, in turn, to the release of cytochrome c and activation of the caspase cascade (Cardoso et al. [2004](#prp2235-bib-0009){ref-type="ref"}; Bajić et al. [2013](#prp2235-bib-0004){ref-type="ref"}). Treatment with Mdivi‐1 has been shown to reduce ROS levels partly by augmenting the activity of intracellular antioxidant enzymes such as superoxide dismutase and catalase (Liu et al. [2015](#prp2235-bib-0044){ref-type="ref"}). The cytoprotective effect of Mdivi‐1 in neurons has also been attributed to the opening of the large‐conductance calcium‐ and voltage‐activated potassium channels (Liu et al. [2015](#prp2235-bib-0044){ref-type="ref"}), which have long been implicated in cytoprotection against ischemic injury in the heart and are found in abundance in the central nervous system (Xu et al. [2002](#prp2235-bib-0081){ref-type="ref"}; Bentzen et al. [2014](#prp2235-bib-0006){ref-type="ref"}). The influx of potassium through these channels in the inner mitochondrial membrane can cause mild uncoupling of oxidative phosphorylation, ultimately inhibiting ROS production via Complex I (Kulawiak et al. [2008](#prp2235-bib-0037){ref-type="ref"}).

In a glutamate toxicity model, Mdivi‐1 has been reported to protect primary rat cortical neurons and HT‐22 cells (immortalized hippocampal neurons), from apoptosis. Moreover, Mdivi‐1 remains protective when given 2--8 h after the onset of glutamate challenge (Grohm et al. [2012](#prp2235-bib-0024){ref-type="ref"}). Using a different injury model, Zhang et al. ([2013c](#prp2235-bib-0084){ref-type="ref"}) has suggested that the therapeutic window of Mdivi‐1 in protecting rat cortical neurons against simulated ischemia‐reperfusion injury is limited to the ischemic period, for Mdivi‐1 fails to confer protection when given during reperfusion. They showed that mitophagy‐mediated mitochondrial clearance during reperfusion after ischemia is neuroprotective and inhibition of mitochondrial fission by Mdivi‐1 may suppress mitophagy and aggravate ischemia‐induced injury (Zhang et al. [2013c](#prp2235-bib-0084){ref-type="ref"}). These studies have demonstrated the importance of precise temporal regulation of the mitochondrial fission protein Drp1, in neurons under different pathophysiological conditions. Whether a similar therapeutic window for Mdivi‐1 is applicable to other types of neurons and other cell types or in other injury models remains unclear and warrants further investigation.

Skeletal myoblasts {#prp2235-sec-0007}
------------------

Mitochondrial dynamics play an important role in mitochondrial quality control and skeletal muscle homeostasis. Dysregulation of mitochondrial dynamics has been implicated in various pathological conditions of muscular dysfunction (Jheng et al. [2015](#prp2235-bib-0030){ref-type="ref"}). Inhibiting mitochondrial fission with Mdivi‐1 has been shown to attenuate palmitate‐induced mitochondrial dysfunction and insulin resistance in C2C12 skeletal myoblasts (Jheng et al. [2012](#prp2235-bib-0029){ref-type="ref"}). In L6 rat skeletal muscle cells, Mdivi‐1 suppressed dexamethasone‐induced autophagic flux and enhanced expression of muscle atrophy‐related genes. This suggests a regulatory role for mitochondrial fission in mitochondrial quality control in skeletal muscles via activation of autophagy (Troncoso et al. [2014](#prp2235-bib-0070){ref-type="ref"}). Mitochondrial dynamics also play a significant role in the myogenic differentiation of myoblasts. Inhibition of Drp1‐mediated mitochondrial fission with Mdivi‐1 impaired myotube formation in both C2C12 myoblasts and primary murine myoblasts, which was accompanied by increased apoptosis and impaired mitochondrial biogenesis (Kim et al. [2013](#prp2235-bib-0036){ref-type="ref"}).

Cancer cells {#prp2235-sec-0008}
------------

In contrast to the cytoprotective effect in cardiovascular cells and neurons, Mdivi‐1 exerts a cytodestructive effect in most hyperproliferative cancer and immortalized cell lines (Table [1](#prp2235-tbl-0001){ref-type="table-wrap"}). A hallmark of cancer cells is their unregulated proliferation and Drp1‐mediated mitochondrial fission has been shown to play an important role in cancer cell growth (Rehman et al. [2012](#prp2235-bib-0060){ref-type="ref"}; Xie et al. [2015](#prp2235-bib-0079){ref-type="ref"}). Inhibiting mitochondrial fission with Mdivi‐1 has been reported to exert a cytotoxic effect on cancer cells by reducing progression of mitosis and inducing apoptosis (Qian et al. [2014](#prp2235-bib-0057){ref-type="ref"}, [2015](#prp2235-bib-0058){ref-type="ref"}; Suzuki‐Karasaki et al. [2015](#prp2235-bib-0066){ref-type="ref"}; Wang et al. [2015a](#prp2235-bib-0073){ref-type="ref"},[b](#prp2235-bib-0074){ref-type="ref"}). As demonstrated in several cancer cell lines, Mdivi‐1 induced G2/M cycle arrest by interfering with DNA replication and synthesis, and activating checkpoint kinase‐1 (Qian et al. [2014](#prp2235-bib-0057){ref-type="ref"}; Wang et al. [2015b](#prp2235-bib-0074){ref-type="ref"}). The mitotic phase specifically is halted by Mdivi‐1 as a result of impaired assembly of mitotic spindles and cytokinesis, consequently disrupting chromosome segregation leading to aneuploidy (Wang et al. [2015a](#prp2235-bib-0073){ref-type="ref"}). Importantly, the proapoptotic and antiproliferative effects of Mdivi‐1 were absent in nontransformed normal human cells such as fibroblasts and epithelial cells, suggesting this effect is selective for tumor cells (Qian et al. [2014](#prp2235-bib-0057){ref-type="ref"}, [2015](#prp2235-bib-0058){ref-type="ref"}; Wang et al. [2015a](#prp2235-bib-0073){ref-type="ref"},[b](#prp2235-bib-0074){ref-type="ref"}; Xie et al. [2015](#prp2235-bib-0079){ref-type="ref"}).

Mdivi‐1 has also been shown to enhance the cytotoxic effect of the anticancer compound cisplatin; it does so by triggering Noxa‐dependent mitochondrial outer membrane permeabilization, bypassing the usual Bax/Bak‐dependency (Qian et al. [2014](#prp2235-bib-0057){ref-type="ref"}). However, whether the cytotoxic effect of Mdivi‐1 actually involves Drp1 remains controversial. Studies which suggest a Drp1‐independent pathway have been conducted in Drp1‐deficient, mouse immortalized embryonic fibroblasts without direct evidence in cancer cells (Qian et al. [2014](#prp2235-bib-0057){ref-type="ref"}, [2015](#prp2235-bib-0058){ref-type="ref"}; Wang et al. [2015a](#prp2235-bib-0073){ref-type="ref"},[b](#prp2235-bib-0074){ref-type="ref"}). There is other indirect evidence suggesting the involvement of the Bax/Bak pathway in the cytotoxic effect of Mdivi‐1, using mouse embryonic fibroblasts deficient in Bax/Bak (Qian et al. [2014](#prp2235-bib-0057){ref-type="ref"}, [2015](#prp2235-bib-0058){ref-type="ref"}; Wang et al. [2015a](#prp2235-bib-0073){ref-type="ref"},[b](#prp2235-bib-0074){ref-type="ref"}). However, just one study in brain tumor initiating cells showed support for the involvement of Drp1 in proliferation and survival of cancer cells, for Drp1 knockdown or treatment with Mdivi‐1 significantly reduced the tumorigenicity of the cells both in vitro and in vivo (Xie et al. [2015](#prp2235-bib-0079){ref-type="ref"}). In this study, the anticancer effect of Mdivi‐1 was suggested to involve upregulation of AMP‐activated protein kinase (AMPK), a downstream enzyme mediator of Drp1 (Xie et al. [2015](#prp2235-bib-0079){ref-type="ref"}).

Therapeutic Potential of Mdivi‐1 {#prp2235-sec-0009}
================================

Several studies in animal disease models have highlighted the therapeutic potential of Mdivi‐1 in settings of ischemia‐reperfusion injury (Table [2](#prp2235-tbl-0002){ref-type="table-wrap"}). In myocardial ischemia‐reperfusion injury, treatment with Mdivi‐1 increased animal survival rate, reduced myocardial infarct size, and improved heart function (Gharanei et al. [2013](#prp2235-bib-0021){ref-type="ref"}; Sharp et al. [2014](#prp2235-bib-0061){ref-type="ref"}, [2015](#prp2235-bib-0062){ref-type="ref"}). Consistent with in vitro findings, the cardioprotective effect of Mdivi‐1 has been associated with activation of Akt signaling, a component of the reperfusion injury salvation kinase (RISK) pathway, and delayed the opening of mitochondrial permeability transition pores (Gharanei et al. [2013](#prp2235-bib-0021){ref-type="ref"}; Ong et al. [2015](#prp2235-bib-0049){ref-type="ref"}). Therapeutic benefits of Mdivi‐1 have also been found in other cardiovascular conditions such as pressure overload‐induced heart failure (Givvimani et al. [2012](#prp2235-bib-0022){ref-type="ref"}), cardiac arrest (Sharp et al. [2015](#prp2235-bib-0062){ref-type="ref"}) and pulmonary artery hypertension (Marsboom et al. [2012](#prp2235-bib-0045){ref-type="ref"}). Regarding vascular diseases, Mdivi‐1 prevented premature ductus arteriosus closure (Hong et al. [2013](#prp2235-bib-0026){ref-type="ref"}) and reduced neointima formation after carotid artery balloon injury (Lim et al. [2015](#prp2235-bib-0042){ref-type="ref"}) by suppressing proliferation of smooth muscle cells and fibrosis (Hong et al. [2013](#prp2235-bib-0026){ref-type="ref"}; Lim et al. [2015](#prp2235-bib-0042){ref-type="ref"}).

Disruption of mitochondrial dynamics has been associated with impaired mitochondrial biogenesis in the brain, which contributes to several neuropathologies. The lipophilic nature of Mdivi‐1 enables the small molecule to penetrate the blood--brain barrier, reaching its peak concentration in brain tissue 4 h after intravenous injection (Cui et al. [2016](#prp2235-bib-0016){ref-type="ref"}), and treatment has enabled cytoprotection against neuronal loss following ischemia‐reperfusion injury, diabetes‐induced neuropathy, virus‐sensory neuropathy, and seizures (Qiu et al. [2013](#prp2235-bib-0059){ref-type="ref"}; Xie et al. [2013](#prp2235-bib-0078){ref-type="ref"}; Zhang et al. [2013b](#prp2235-bib-0083){ref-type="ref"}; Zhao et al. [2014](#prp2235-bib-0085){ref-type="ref"}; Huang et al. [2015](#prp2235-bib-0027){ref-type="ref"}; Cui et al. [2016](#prp2235-bib-0016){ref-type="ref"}; Kanda et al. [2016](#prp2235-bib-0031){ref-type="ref"}). The neuroprotective effect of Mdivi‐1 is manifest as improved brain hemodynamics and neurological outcome (Zhao et al. [2014](#prp2235-bib-0085){ref-type="ref"}; Li et al. [2015a](#prp2235-bib-0040){ref-type="ref"},[b](#prp2235-bib-0041){ref-type="ref"}; Liu et al. [2015](#prp2235-bib-0044){ref-type="ref"}), and the beneficial effects were associated with reduced ROS levels (Qiu et al. [2013](#prp2235-bib-0059){ref-type="ref"}; Li et al. [2015a](#prp2235-bib-0040){ref-type="ref"}; Kanda et al. [2016](#prp2235-bib-0031){ref-type="ref"}), enhanced activity of antioxidant enzymes (Qiu et al. [2013](#prp2235-bib-0059){ref-type="ref"}; Li et al. [2015a](#prp2235-bib-0040){ref-type="ref"}), preserved mitochondrial function (Huang et al. [2015](#prp2235-bib-0027){ref-type="ref"}; Cui et al. [2016](#prp2235-bib-0016){ref-type="ref"}), and increased expression of large‐conductance Ca^2+^ and voltage‐activated K^+^ channels (Liu et al. [2015](#prp2235-bib-0044){ref-type="ref"}).

The therapeutic potential of Mdivi‐1 has also been reported in other organs such as retina (Park et al. [2011](#prp2235-bib-0052){ref-type="ref"}), kidney (Tang et al. [2013](#prp2235-bib-0068){ref-type="ref"}) and liver (Gonzalez et al. [2014](#prp2235-bib-0023){ref-type="ref"}), where in vivo administration of Mdivi‐1 conferred cytoprotection of important cell types in these organs (i.e., retinal ganglion cells, renal tubular epithelial cells, and hepatocytes, respectively). Despite these promising results, many challenges (as discussed in the next section) await before Mdivi‐1 might be suitable for patients.

Future Perspectives {#prp2235-sec-0010}
===================

In addition to cell survival, mitochondrial fission plays important roles in related cellular functions such as proliferation and differentiation which are particularly important in organ development. Permanent alterations of mitochondrial dynamics are detrimental, often leading to mitochondrial diseases such as autosomal dominant optical atrophy (heterozygous mutation in Opa1), Charcot‐Marie‐Tooth type 2A neuropathy (heterozygous mutations in Mfn2) and abnormal brain development (A395D mutation in Drp1). The physiological importance of mitochondrial dynamics in the heart has also been demonstrated in various mouse models with genetic deletion of mitochondrial fusion (Mfn1, Mfn2, and Opa1) or fission (Drp1, Mff, and Fis1) proteins, exhibiting developmental cardiac defects and increased susceptibility to cardiac injury (Chan [2012](#prp2235-bib-0011){ref-type="ref"}; Babbar and Sheikh [2013](#prp2235-bib-0003){ref-type="ref"}). Therefore, pharmacological agents such as Mdivi‐1, that allow timely and reversible manipulation of mitochondrial morphology in different pathological conditions may have therapeutic potential. However, effective application of Mdivi‐1 to manipulate mitochondrial dynamics will require further studies to identify the optimal therapeutic window through a better understanding of the temporal correlation between disease progression and changes in mitochondrial morphology, which can often be disease‐specific.

The divergent effects of Mdivi‐1 on cell survival is likely to be dependent on cell type. While Mdivi‐1 exerts protection of cardiovascular cells and neurons, this small molecule is toxic to hyperproliferative cells such as cancer cells and most immortalized cell lines (Table [1](#prp2235-tbl-0001){ref-type="table-wrap"}). The differential effects of Mdivi‐1 on cell survival could also be attributed to the duration of treatment. Most in vitro studies showing the cytotoxic effect of Mdivi‐1 were conducted for longer than 16 h of treatment, whereas studies reporting the cytoprotective effect of Mdivi‐1 were performed in much shorter duration (≤8 h treatment) (Table [1](#prp2235-tbl-0001){ref-type="table-wrap"}). This suggests that chronic inhibition of Drp1 with Mdivi‐1 might well be detrimental to cell function and survival.

Although the precise mechanisms underlying the differential effects of Mdivi‐1 on cell survival remain unclear, Drp1 has been shown to interact with various proteins, such as Cdk1/cyclin B, SUMO1/Sentrin/SMT3 Specific Peptidase 3 (SENP3), Bax/Bak, Noxa, protein kinase A, AMPK, Akt, and Erk2, depending on its posttranslational modification (Chang and Blackstone [2007](#prp2235-bib-0012){ref-type="ref"}; Taguchi et al. [2007](#prp2235-bib-0067){ref-type="ref"}; Wasiak et al. [2007](#prp2235-bib-0075){ref-type="ref"}; Guo et al. [2013](#prp2235-bib-0025){ref-type="ref"}; Jheng et al. [2015](#prp2235-bib-0030){ref-type="ref"}; Kashatus et al. [2015](#prp2235-bib-0035){ref-type="ref"}). In this regard, further investigation of functional outcomes which result from different posttranslational modifications of Drp1 will provide more mechanistic insights on the cytoprotective and cytotoxic effects of Mdivi‐1.

The pharmacokinetics and cytotoxic profile of Mdivi‐1 remain poorly understood. Cui et al. ([2016](#prp2235-bib-0016){ref-type="ref"}) is the only in vivo pharmacokinetic profile of Mdivi‐1 conducted to date, and they found intraperitoneal administration of Mdivi‐1 at 20 mg/kg resulted in peak plasma and brain concentrations 2 and 4 h later, respectively, with a half‐life estimated at 12 h (Cui et al. [2016](#prp2235-bib-0016){ref-type="ref"}). Future studies should also characterize the pharmacokinetics of Mdivi‐1 via intravenous injection, a more common route of drug administration for patients. Furthermore, the toxicological profile of Mdivi‐1 is yet to be fully established. An in vitro study in the HL‐1 cardiac cell line has shown that Mdivi‐1 can inhibit potassium channels which resulted in longer duration and increased firing rate of action potentials, suggesting a potential arrhythmogenic effect of Mdivi‐1 (So et al. [2012](#prp2235-bib-0064){ref-type="ref"}). However, the relevance of this observation should be confirmed in primary cardiomyocytes and in vivo by electrophysiological studies of the heart muscle. Future studies should also investigate the physiological effect of the active metabolites of Mdivi‐1 to ensure that they are devoid of undersirable biological effects, as aprerequisite to advance Mdivi‐1 closer to clinical application.

In summary, current preclinical studies have demonstrated therapeutic potential of Mdivi‐1 as a cytoprotective, as well as an anticancer agent. However, many challenges and uncertainties remain to be addressed before such drugs might be applied clinically. The mechanism of action by which Mdivi‐1 affects cell survival also remains unclear. The pharmacokinetics (absorption, distribution, metabolism, and excretion) and toxicology profiles of Mdivi‐1 await further study before clinical translation. Moreover, the lipophilicity (i.e., poor water solubility) of Mdivi‐1 may limit its utility, and new Drp1 inhibitors with better specificity, potency, and solubility are highly desirable.
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